RxDoctor Payments Data

Bienvenido Fajardo, MD

Internal Medicine · New York, NYNPI 1528153467

Payments from drug & device makers

$953in general payments, 2019–2025

Across 37 payments — averaging $25.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$259
  • Abbott$141
  • Boehringer Ingelheim$124
  • Novo Nordisk$88
  • AbbVie$69
  • Bayer$56
  • plus $217 from 6 others

What the payments were for

  • Food & beverage$953100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$953 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$31,239
Medicare patients
92
Services billed
719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin230$265,352
TrulicityDulaglutide156$230,547
JanuviaSitagliptin Phosphate125$135,765
OzempicSemaglutide102$123,204
FarxigaDapagliflozin Propanediol99$118,265
JanumetSitagliptin Phos/Metformin Hcl68$76,204
EliquisApixaban69$74,661
EntrestoSacubitril/Valsartan32$53,179
VascepaIcosapent Ethyl96$44,939
RybelsusSemaglutide27$44,472
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate15$40,721
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog131$40,021
LinzessLinaclotide38$36,667
LokelmaSodium Zirconium Cyclosilicate45$36,076
XareltoRivaroxaban34$26,224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$124$303,736258 claims
Novo NordiskOzempic, Rybelsus$88$167,677129 claims
AstraZenecaFarxiga, Lokelma, Brilinta$37$166,653158 claims
NovartisEntresto$259$53,17932 claims
AbbVieLinzess, Lumigan, Combigan$69$49,63361 claims
BayerKerendia$56$9,82114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →